Vaccine Research Center
Division of US Department of Health and Human Services
Latest From Vaccine Research Center
Swiss pharma licenses rights to a pair of preclinical, multi-antigen DNA immunotherapies for prostate cancer and hepatitis B, as well as delivery technology. Inovio gets $10 million up front and can earn milestones up to $412.5 million.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.